Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
Clinical trial NCT01307618 · TERMINATED
Trial details
- NCT number
- NCT01307618
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2015-01-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.